Gilead Sciences, Inc. (NASDAQ:GILD)‘s stock had its “outperform” rating restated by analysts at Robert W. Baird in a report issued on Tuesday. They currently have a $87.00 price objective on the biopharmaceutical company’s stock. Robert W. Baird’s price objective suggests a potential upside of 16.95% from the company’s previous close.

GILD has been the topic of a number of other research reports. Zacks Investment Research upgraded Gilead Sciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 11th. William Blair reiterated an “outperform” rating on shares of Gilead Sciences in a report on Friday, June 16th. Jefferies Group LLC reiterated a “buy” rating and set a $82.00 price objective on shares of Gilead Sciences in a report on Thursday, April 6th. Morgan Stanley reiterated an “equal weight” rating on shares of Gilead Sciences in a report on Tuesday, July 11th. Finally, Credit Suisse Group reiterated an “outperform” rating and set a $79.00 price objective on shares of Gilead Sciences in a report on Friday, May 5th. Fifteen investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $80.09.

Gilead Sciences (GILD) traded down 0.44% during mid-day trading on Tuesday, reaching $74.06. The company’s stock had a trading volume of 5,767,175 shares. The company has a market cap of $96.78 billion, a price-to-earnings ratio of 7.83 and a beta of 1.20. Gilead Sciences has a 12 month low of $63.76 and a 12 month high of $84.15. The stock’s 50 day moving average is $68.84 and its 200 day moving average is $68.56.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.18 by $0.02. Gilead Sciences had a return on equity of 76.64% and a net margin of 43.42%. The firm had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.66 billion. Equities research analysts predict that Gilead Sciences will post $8.42 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Gilead Sciences, Inc. (GILD) Given Outperform Rating at Robert W. Baird” was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/07/25/gilead-sciences-inc-gild-given-outperform-rating-at-robert-w-baird.html.

In other news, Director John Francis Cogan sold 9,943 shares of the company’s stock in a transaction on Tuesday, May 9th. The stock was sold at an average price of $67.25, for a total transaction of $668,666.75. Following the completion of the sale, the director now directly owns 47,562 shares in the company, valued at approximately $3,198,544.50. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total value of $5,206,643.00. Following the sale, the insider now owns 3,199,969 shares of the company’s stock, valued at $227,197,799. The disclosure for this sale can be found here. Insiders sold a total of 88,276 shares of company stock valued at $6,230,610 over the last 90 days. 1.30% of the stock is currently owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in the stock. Proficio Capital Partners bought a new stake in Gilead Sciences during the fourth quarter worth $26,000. Van Hulzen Asset Management LLC increased its stake in Gilead Sciences by 9.1% in the second quarter. Van Hulzen Asset Management LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 100 shares during the last quarter. Hall Laurie J Trustee increased its stake in Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 250 shares during the last quarter. Penserra Capital Management LLC increased its stake in Gilead Sciences by 148.3% in the third quarter. Penserra Capital Management LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 774 shares during the last quarter. Finally, Gemmer Asset Management LLC increased its stake in Gilead Sciences by 15.5% in the third quarter. Gemmer Asset Management LLC now owns 1,301 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 175 shares during the last quarter. Hedge funds and other institutional investors own 74.05% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.